EPRX
Eupraxia Pharmaceuticals Inc. NASDAQ Listed Apr 5, 2024$7.58
After hrs
$7.83
+3.30%
Mkt Cap $253.8M
52w Low $3.67
69.2% of range
52w High $9.32
50d MA $7.40
200d MA $6.68
P/E (TTM)
-7.5x
EV/EBITDA
-5.7x
P/B
3.9x
Debt/Equity
0.0x
ROE
—
P/FCF
-10.2x
RSI (14)
—
ATR (14)
—
Beta
1.42
50d MA
$7.40
200d MA
$6.68
Avg Volume
224.8K
About
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for t…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.16 | -0.37 | -131.2% | 7.50 | -0.5% | -1.9% | -1.5% | +1.1% | +0.1% | +1.3% | — |
| Nov 4, 2025 | AMC | -0.23 | -0.19 | +17.4% | 5.45 | +0.0% | +4.0% | +2.4% | +0.0% | +14.3% | +19.8% | — |
| Aug 12, 2025 | AMC | -0.21 | -0.26 | -23.8% | 5.37 | +2.6% | +1.5% | -1.7% | -0.9% | -1.3% | +0.4% | — |
| May 6, 2025 | AMC | -0.19 | -0.21 | -10.5% | 4.06 | -5.2% | -6.7% | -6.4% | -6.4% | -7.4% | -4.7% | — |
| Mar 20, 2025 | AMC | -0.18 | -0.21 | -16.7% | 3.91 | +1.0% | -2.3% | -6.9% | -9.5% | -13.6% | -13.6% | — |
| Nov 7, 2024 | AMC | -0.13 | -0.17 | -30.1% | 3.16 | +0.9% | +1.6% | -4.7% | -8.2% | -10.1% | -8.2% | — |
| Aug 7, 2024 | AMC | -0.17 | -0.17 | -0.4% | 2.39 | +1.7% | +5.4% | +12.1% | +13.8% | +4.2% | +9.2% | — |
| May 8, 2024 | AMC | -0.17 | -0.21 | -23.2% | 2.90 | +1.0% | +1.0% | +0.0% | +0.0% | +1.7% | +2.8% | — |
| Mar 21, 2024 | AMC | — | -0.15 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.11 | -0.25 | -124.1% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.02 | $7.08 | +0.9% | +0.6% | +3.3% | +2.0% | +2.7% | +1.3% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.39 | $7.36 | -0.4% | +2.6% | +1.6% | +2.8% | -3.9% | -0.8% |
| Jan 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.43 | $8.56 | +1.5% | +4.0% | +3.8% | +7.0% | +7.1% | +6.9% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.59 | $8.52 | -0.8% | -5.5% | -4.5% | -3.3% | -1.9% | +2.1% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.46 | +1.3% | -1.7% | -3.3% | -2.0% | -3.0% | -6.3% |
Data updated apr 25, 2026 7:26am
· Source: massive.com